Back to top
more

Mylan N.V. (MYL)

(Delayed Data from NSDQ)

$28.01 USD

28.01
4,315,758

+0.33 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $28.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Mylan (MYL) Down 12.6% Since Earnings Report: Can It Rebound?

Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Is Mylan N.V. (MYL) a Great Stock for Value Investors?

    Is Mylan N.V. a great pick from the value investor's perspective right now? Read on to know more.

      Parth Panchal headshot

      Trump's Tweet Hits Pharma Stocks, Promises Decreased Drug Prices

      A President Donald Trump tweet promising to increase competition and decrease prices in the drug industry sent pharmaceutical stocks falling on Tuesday.

        The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi

        The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi

          Theravance (TBPH) Q4 Loss Wider than Expected, Revenues Beat

          Theravance Biopharma, Inc. (TBPH) reported fourth-quarter 2016 loss of $1.36 per share, much wider than both the Zacks Consensus Estimate of a loss of $1.07 and the year-ago loss of $1.23.

            Mylan (MYL) to Post Q4 Earnings: Will the Stock Disappoint?

            Mylan N.V. (MYL) is scheduled to report fourth-quarter 2016 results on Mar 1, after the market closes.

              Tracey Ryniec headshot

              Where Are the Best Buying Opportunities in Stocks Right Now?

              With stocks hitting new record highs, you might think there???s nothing left to buy. But some of the biggest money managers beg to differ.

                Mylan's Proposed Biosimailar for Cancer Under Review in U.S.

                Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.

                  Madeleine Johnson headshot

                  CVS Debuts Cheap EpiPen Alternative

                  On Thursday, leading drug store chain CVS Health Corp. (CVS) announced that it is now selling a cheaper alternative to Mylan's (MYL) EpiPen.

                    Valeant Streamlines Portfolio with Skincare Brands Sale

                    Beleaguered Valeant Pharmaceuticals International, Inc. (VRX) announced that it has entered into an agreement to sell its CeraVe, AcneFree and AMBI skincare brands to L'Or??al for $1.3 billion in cash.

                      Valeant to Sell Dendreon Unit to Sanpower for $820 Million

                      Beleaguered Valeant Pharmaceuticals International, Inc. (VRX) announced that it will sell all the outstanding equity interests in Dendreon Pharmaceuticals, Inc. to the China based Sanpower Group Co., Ltd.

                        Is Valeant (VRX) Fated for Terrible 2017 As Well?

                        Shares of Valeant Pharmaceuticals, Inc. (VRX) slumped 85.3% in 2016, eroding a chunk of shareholders' net worth.

                          Company News for January 03, 2017

                          Companies In The News are: MYL,JNJ,GPOR,PBR,S,TMUS

                            Mylan (MYL) Announces Multiple Generic Launches in the U.S.

                            Mylan (MYL) announced quite a few generic launches in the U.S. in Dec 2016.

                              Mylan/Biocon's Herceptin Biosimilar Phase III Data Published

                              Mylan (MYL) and partner Biocon's biosimilar version of Herceptin phase III data published in JAMA.

                                Mylan (MYL) Launches Authorized Generic EpiPen at $300

                                Mylan (MYL) announced the launch of the first generic version of its life-saving allergy treatment, EpiPen, at more than 50% discount to the branded product.

                                  Pfizer (PFE) Fined for Price Hike of Anti-Epilepsy Drug in UK

                                  Pfizer (PFE) fined for hiking price of an anti-epilepsy drug by up to 2,600% by the Competition and Markets Authority of the UK.

                                    Ryan McQueeney headshot

                                    Trump Vows to Slash Drug Prices, Sends Biotech Stocks Lower

                                    Shares of the iShares Nasdaq Biotechnology ETF (IBB) are down more than 3.6% in morning trading Wednesday following a new warning from President-elect Donald Trump that he will indeed be targeting high drug prices.

                                      Stock Market News for November 10, 2016

                                      Benchmarks finished higher on Wednesday as investors embraced the election of Republican Donald Trump as the president of the United States

                                        Madeleine Johnson headshot

                                        Mylan (MYL) Misses Q3 Earnings, Reiterates 2016 EPS Forecast

                                        Mylan NV (MYL) just released its third quarter fiscal 2016 financial results, posting earnings of $1.38 per share and revenues of $3.06 billion.

                                          Eric Dutram headshot

                                          Your Two Minute Earnings Preview for Mylan (MYL) Stock

                                          Drug companies have been under pressure thanks to worries over politics and growth. Can Mylan give investors some much needed optimism when it reports later this week?

                                            David Bartosiak headshot

                                            The Best Options Trade for Mylan (MYL) Earnings

                                            Join Dave Bartosiak at 1:30pm Central Time on Monday, November 7th, to see his thoughts on Mylan (MYL) before they report earnings with real-time options insight.

                                              Zacks Industry Outlook Highlights: Mylan, Lilly, Pfizer, Novartis and Amgen

                                              Zacks Industry Outlook Highlights: Mylan, Lilly, Pfizer, Novartis and Amgen

                                                Pricing Issues Continue to Weigh on the Pharma Sector

                                                With generics and biosimilars on the rise, many pharma companies are looking towards new products to pick up the pace and make up for lost sales.

                                                  Arpita Dutt headshot

                                                  Pharma Industry Outlook - November 2016

                                                  It's been a rough year for pharma and biotech stocks, with media and political focus on the high price of drugs, mixed performance results, slower-than-expected new product launches and increasing competition.